Uniseed is a venture fund operating at the Universities of Melbourne, Queensland and New South Wales, with investment capital provided by the three universities and AustralianSuper – a leading industry superannuation fund. Uniseed’s mandate is to facilitate the commercialisation of university-generated intellectual property by targeted investment in highly promising technologies.
Uniseed’s investments cover a range of technology sectors. To date, the fund has exited two investments through trade sales; an IT security technology (Vintela) and a semi-conductor technology (Fultec). Its biotechnology portfolio is also maturing, with QRxPharma having submitted an NDA for its dual opioid therapy, and three other companies having completed Phase 2 clinical trials with novel therapies for neuropathic pain (Spinifex), diabetes (Verva) or human head lice (Hatchtech).